Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name BRAF V600E CD274 pos
Gene Variant Detail

BRAF V600E (gain of function)

CD274 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E CD274 pos lung adenocarcinoma predicted - sensitive Dabrafenib Case Reports/Case Series Actionable In a clinical case study, a patient with CD274 (PD-L1)-positive (IHC = 90% of tumor cells) metastatic lung adenocarcinoma harboring BRAF V600E achieved a partial response to treatment with Tafinlar (dabrafenib) and remained stable with improved performance status for 18 months until disease progression, and subsequently achieved a response to Keytruda (pembrolizumab) treatment (PMID: 29142786). 29142786
BRAF V600E CD274 pos lung adenocarcinoma predicted - sensitive Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with CD274 (PD-L1)-positive (IHC = 90% of tumor cells) metastatic lung adenocarcinoma who progressed after an 18-month response to Tafinlar (dabrafenib) treatment based on the presence of BRAF V600E, was then treated with Keytruda (pembrolizumab) for two cycles, and achieved an early response and remained progression-free 7 months after initiating immunotherapy (PMID: 29142786). 29142786
BRAF V600E CD274 pos glioblastoma predicted - sensitive Binimetinib + Encorafenib + Nivolumab + Temozolomide Case Reports/Case Series Actionable In a clinical case study, the addition of Mektovi (binimetinib) and Braftovi (encorafenib) to treatment with the combination of Opdivo (nivolumab) and Temodar (temozolomide) resulted in a complete response after 6 months in a patient with CD274 (PD-L1), PDCD1 (PD-1)-positive glioblastoma harboring BRAF V600E, and the patient remained progression-free for at least 20 months while on treatment (PMID: 39036436). 39036436